JP6279605B2 - 自己免疫疾患および炎症性疾患の処置に使用するためのレチノイド関連オーファン受容体ガンマ（ＲＯＲγ）のモジュレーター - Google Patents
自己免疫疾患および炎症性疾患の処置に使用するためのレチノイド関連オーファン受容体ガンマ（ＲＯＲγ）のモジュレーター Download PDFInfo
- Publication number
- JP6279605B2 JP6279605B2 JP2015546002A JP2015546002A JP6279605B2 JP 6279605 B2 JP6279605 B2 JP 6279605B2 JP 2015546002 A JP2015546002 A JP 2015546002A JP 2015546002 A JP2015546002 A JP 2015546002A JP 6279605 B2 JP6279605 B2 JP 6279605B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- mmol
- fluoro
- methylpiperazin
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- ZZHSNFGJLRDKDJ-KKFHFHRHSA-N CC(C1CC1)C(N1[C@@H](C)CN(Cc2c(C)c(NC(c3cnc(C)cc3)=O)cc(F)c2)CC1)=O Chemical compound CC(C1CC1)C(N1[C@@H](C)CN(Cc2c(C)c(NC(c3cnc(C)cc3)=O)cc(F)c2)CC1)=O ZZHSNFGJLRDKDJ-KKFHFHRHSA-N 0.000 description 1
- SAHPQPLXRDAREO-LROBGIAVSA-N CC(C1CCC1)C(N1[C@@H](C)CN(Cc2c(C)c(NC(c3cnc(C)cc3)=O)cc(F)c2)CC1)=O Chemical compound CC(C1CCC1)C(N1[C@@H](C)CN(Cc2c(C)c(NC(c3cnc(C)cc3)=O)cc(F)c2)CC1)=O SAHPQPLXRDAREO-LROBGIAVSA-N 0.000 description 1
- IIFIGGNBUOZGAB-UHFFFAOYSA-N CCOC(C(CCC1)C1O)=O Chemical compound CCOC(C(CCC1)C1O)=O IIFIGGNBUOZGAB-UHFFFAOYSA-N 0.000 description 1
- UVCBVFKFFBLKFZ-ZDUSSCGKSA-N C[C@@H](CN(Cc1c(C)c(N)ccc1F)CC1)N1C(C1CCCC1)=O Chemical compound C[C@@H](CN(Cc1c(C)c(N)ccc1F)CC1)N1C(C1CCCC1)=O UVCBVFKFFBLKFZ-ZDUSSCGKSA-N 0.000 description 1
- NTIWLXJICXYCMM-HDICACEKSA-N C[C@H](CN(CC(CCC=C1NC(c2cc(Cl)ccc2)=O)=C1Cl)C[C@@H]1C)N1C(C1CCCC1)=O Chemical compound C[C@H](CN(CC(CCC=C1NC(c2cc(Cl)ccc2)=O)=C1Cl)C[C@@H]1C)N1C(C1CCCC1)=O NTIWLXJICXYCMM-HDICACEKSA-N 0.000 description 1
- LICJJUIDCXFZMW-UHFFFAOYSA-N Cc(c(C=O)c(cc1)F)c1[N+]([O-])=O Chemical compound Cc(c(C=O)c(cc1)F)c1[N+]([O-])=O LICJJUIDCXFZMW-UHFFFAOYSA-N 0.000 description 1
- OVEMFXRHESVQEF-UHFFFAOYSA-N Cc(c(CO)cc(F)c1)c1[N+]([O-])=O Chemical compound Cc(c(CO)cc(F)c1)c1[N+]([O-])=O OVEMFXRHESVQEF-UHFFFAOYSA-N 0.000 description 1
- LWWXIFDDFXCLPS-UHFFFAOYSA-N OC(C1(CCCC1)F)=O Chemical compound OC(C1(CCCC1)F)=O LWWXIFDDFXCLPS-UHFFFAOYSA-N 0.000 description 1
- YBLIEGZPJGIRIS-UHFFFAOYSA-N [O-][N+](c1cccc2c1CCC2Cl)=O Chemical compound [O-][N+](c1cccc2c1CCC2Cl)=O YBLIEGZPJGIRIS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2012/001636 | 2012-12-06 | ||
| CN2012001636 | 2012-12-06 | ||
| CN2013000182 | 2013-02-25 | ||
| CNPCT/CN2013/000182 | 2013-02-25 | ||
| CN2013000803 | 2013-07-01 | ||
| CNPCT/CN2013/000803 | 2013-07-01 | ||
| PCT/EP2013/075594 WO2014086894A1 (en) | 2012-12-06 | 2013-12-05 | Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501250A JP2016501250A (ja) | 2016-01-18 |
| JP2016501250A5 JP2016501250A5 (enExample) | 2017-01-19 |
| JP6279605B2 true JP6279605B2 (ja) | 2018-02-14 |
Family
ID=49709687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015546002A Expired - Fee Related JP6279605B2 (ja) | 2012-12-06 | 2013-12-05 | 自己免疫疾患および炎症性疾患の処置に使用するためのレチノイド関連オーファン受容体ガンマ（ＲＯＲγ）のモジュレーター |
Country Status (33)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3027616B1 (en) | 2013-07-30 | 2018-01-10 | Boehringer Ingelheim International GmbH | Azaindole compounds as modulators of rorc |
| RS59007B1 (sr) | 2014-02-03 | 2019-08-30 | Vitae Pharmaceuticals Llc | Dihidropirolopiridinski inhibitori ror-gama |
| BR112016027732B1 (pt) * | 2014-05-28 | 2023-11-07 | Glaxosmithkline Intellectual Property Development Limited | Composto modulador do receptor gama, composição farmacêutica que compreende o referido composto, bem como uso do mesmo para o tratamento de doenças inflamatórias e autoimunes mediadas por rory |
| CA2950220A1 (en) | 2014-05-28 | 2015-12-03 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds |
| JP6522665B2 (ja) * | 2014-05-28 | 2019-05-29 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 新規化合物 |
| CN104292208A (zh) * | 2014-09-09 | 2015-01-21 | 上海师范大学 | 7-苯基-6,8-二氧杂螺[3.5]壬烷-2-羧酸及其制备方法 |
| MA40759A (fr) | 2014-09-26 | 2017-08-01 | Pfizer | Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation |
| EA031967B1 (ru) | 2014-10-14 | 2019-03-29 | Вайтаи Фармасьютиклз, Инк. | ДИГИДРОПИРРОЛОПИРИДИНОВЫЕ ИНГИБИТОРЫ ROR-γ |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| TW201625588A (zh) * | 2014-11-05 | 2016-07-16 | 第一三共股份有限公司 | 環狀胺衍生物 |
| US10336748B2 (en) | 2015-01-30 | 2019-07-02 | Pfizer Inc. | Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof |
| WO2017024018A1 (en) | 2015-08-05 | 2017-02-09 | Vitae Pharmaceuticals, Inc. | Modulators of ror-gamma |
| KR20180086221A (ko) * | 2015-11-20 | 2018-07-30 | 비타이 파마슈티컬즈, 인코포레이티드 | Ror-감마의 조절물질 |
| TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| EP3484880B1 (en) * | 2016-07-13 | 2020-09-02 | Leo Pharma A/S | Heteroaromatic modulators of the retinoid-related orphan receptor gamma |
| CN109134476B (zh) * | 2017-06-15 | 2021-03-19 | 复旦大学 | 桥环哌嗪类衍生物或其盐及其制备方法和用途 |
| EP3619188B1 (en) * | 2017-07-18 | 2020-10-07 | Lonza Ltd | Method for preparation of 5-fluoro-2-methyl-3-nitrobenzoic acid and its methyl ester |
| MA49685A (fr) | 2017-07-24 | 2021-04-14 | Vitae Pharmaceuticals Llc | INHIBITEURS DE ROR gamma |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| CN108752185A (zh) * | 2018-07-17 | 2018-11-06 | 成都道合尔医药技术有限公司 | 一种1-氟-环戊甲酸的合成方法 |
| CN109438423A (zh) * | 2018-09-12 | 2019-03-08 | 通化师范学院 | 一种肺癌靶向化合物azd-3759的合成工艺的新方法 |
| CN110862319A (zh) * | 2019-12-04 | 2020-03-06 | 深圳振强生物技术有限公司 | 奥扎格雷杂质的制备方法 |
| WO2023232870A1 (en) | 2022-05-31 | 2023-12-07 | Immunic Ag | Rorg/rorgt modulators for the treatment of virus infections like covid-19 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7790726B2 (en) | 2005-08-16 | 2010-09-07 | Chemocentryx, Inc. | Monocyclic and bicyclic compounds and methods of use |
| US20070208000A1 (en) * | 2005-12-15 | 2007-09-06 | Morgan Bradley P | Certain chemical entities, compositions and methods |
| US7825120B2 (en) * | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| US7989455B2 (en) * | 2005-12-19 | 2011-08-02 | Cytokinetics, Inc. | Compounds, compositions and methods |
| WO2012028100A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
| WO2012027965A1 (en) * | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
| WO2012100734A1 (en) | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Compounds useful as retinoid-related orphan receptor gamma modulators |
| WO2012100732A1 (en) | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof |
| EP2511263A1 (en) * | 2011-04-14 | 2012-10-17 | Phenex Pharmaceuticals AG | Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases |
| WO2012145254A2 (en) | 2011-04-16 | 2012-10-26 | Board Of Regents, The University Of Texas System | Methods of using inhibitors of rorϒt to treat disease |
| TWI532728B (zh) * | 2011-04-28 | 2016-05-11 | 日本煙草產業股份有限公司 | 醯胺化合物及其醫藥用途 |
| US9586928B2 (en) * | 2011-05-16 | 2017-03-07 | The Scripps Research Institute | Modulators of the nuclear hormone receptor ROR |
| MX2014002810A (es) | 2011-09-09 | 2014-09-08 | Univ New York | Compuestos amido como moduladores del receptor nuclear huérfanoyt y usos de los mismos. |
| GB201116641D0 (en) | 2011-09-27 | 2011-11-09 | Glaxo Group Ltd | Novel compounds |
| CN104379559B (zh) | 2012-04-27 | 2016-11-09 | 葛兰素集团有限公司 | 化合物 |
| GB201207406D0 (en) | 2012-04-27 | 2012-06-13 | Glaxo Group Ltd | Novel compounds |
| WO2013171729A2 (en) | 2013-01-08 | 2013-11-21 | Glenmark Pharmaceuticals S.A. | Aryl and heteroaryl amide compounds as rorgamat modulator |
| WO2015061686A2 (en) | 2013-10-25 | 2015-04-30 | St. Jude Children's Research Hospital, Inc. | Retinoid x receptor-gamma agonists and retinoid x receptor-alpha antagonists for treatment of cancer |
| JP2016534085A (ja) | 2013-10-25 | 2016-11-04 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 新規化合物 |
| CA2950220A1 (en) | 2014-05-28 | 2015-12-03 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds |
| JP6522665B2 (ja) | 2014-05-28 | 2019-05-29 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 新規化合物 |
| BR112016027732B1 (pt) | 2014-05-28 | 2023-11-07 | Glaxosmithkline Intellectual Property Development Limited | Composto modulador do receptor gama, composição farmacêutica que compreende o referido composto, bem como uso do mesmo para o tratamento de doenças inflamatórias e autoimunes mediadas por rory |
-
2013
- 2013-12-05 SG SG11201504200TA patent/SG11201504200TA/en unknown
- 2013-12-05 HU HUE13799318A patent/HUE033212T2/hu unknown
- 2013-12-05 EP EP13799318.4A patent/EP2928885B1/en active Active
- 2013-12-05 SI SI201330650A patent/SI2928885T1/sl unknown
- 2013-12-05 RS RS20170372A patent/RS55875B1/sr unknown
- 2013-12-05 ME MEP-2017-117A patent/ME02696B/me unknown
- 2013-12-05 DK DK13799318.4T patent/DK2928885T3/en active
- 2013-12-05 AU AU2013354109A patent/AU2013354109B2/en not_active Ceased
- 2013-12-05 CN CN201380070619.3A patent/CN105121430B/zh active Active
- 2013-12-05 LT LTEP13799318.4T patent/LT2928885T/lt unknown
- 2013-12-05 JP JP2015546002A patent/JP6279605B2/ja not_active Expired - Fee Related
- 2013-12-05 PL PL13799318T patent/PL2928885T3/pl unknown
- 2013-12-05 AR ARP130104518A patent/AR093818A1/es unknown
- 2013-12-05 EA EA201591059A patent/EA026437B1/ru not_active IP Right Cessation
- 2013-12-05 UY UY0001035174A patent/UY35174A/es unknown
- 2013-12-05 TW TW102144579A patent/TW201427959A/zh unknown
- 2013-12-05 SM SM20170281T patent/SMT201700281T1/it unknown
- 2013-12-05 MX MX2015007180A patent/MX2015007180A/es unknown
- 2013-12-05 PT PT137993184T patent/PT2928885T/pt unknown
- 2013-12-05 EP EP17157475.9A patent/EP3219711A1/en not_active Withdrawn
- 2013-12-05 WO PCT/EP2013/075594 patent/WO2014086894A1/en not_active Ceased
- 2013-12-05 CA CA2894016A patent/CA2894016C/en active Active
- 2013-12-05 HR HRP20170638TT patent/HRP20170638T1/hr unknown
- 2013-12-05 PE PE2015000712A patent/PE20151144A1/es not_active Application Discontinuation
- 2013-12-05 US US14/649,585 patent/US10005731B2/en active Active
- 2013-12-05 KR KR1020157017633A patent/KR20150092244A/ko not_active Ceased
- 2013-12-05 ES ES13799318.4T patent/ES2626390T3/es active Active
- 2013-12-05 BR BR112015013137-9A patent/BR112015013137B1/pt active IP Right Grant
-
2015
- 2015-05-22 ZA ZA2015/03666A patent/ZA201503666B/en unknown
- 2015-05-28 IL IL239082A patent/IL239082A0/en unknown
- 2015-06-02 PH PH12015501244A patent/PH12015501244A1/en unknown
- 2015-06-05 CL CL2015001557A patent/CL2015001557A1/es unknown
- 2015-06-08 CR CR20150302A patent/CR20150302A/es unknown
-
2017
- 2017-06-02 CY CY20171100587T patent/CY1118932T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6279605B2 (ja) | 自己免疫疾患および炎症性疾患の処置に使用するためのレチノイド関連オーファン受容体ガンマ（ＲＯＲγ）のモジュレーター | |
| KR102093608B1 (ko) | 이미다조피리딘 화합물 | |
| ES2426407T3 (es) | Compuestos de pirrolo[2,3-d]pirimidina | |
| JP6759110B2 (ja) | 新規な化合物 | |
| IL310377A (en) | Novel aryl ether substituted heterocyclic compound as glp1r agonist | |
| AU2005262330A1 (en) | Piperidine derivatives as NK1 antagonists | |
| EP2804861A1 (en) | Substituted pyrimidine compounds and their use as syk inhibitors | |
| CN110997653A (zh) | 芳基杂环哌啶酮甲酰肽2受体和甲酰肽1受体激动剂 | |
| CN117561238A (zh) | 苯基脲衍生物 | |
| JP6522665B2 (ja) | 新規化合物 | |
| JP2017516800A (ja) | 新規な化合物 | |
| CN119730843A (zh) | 取代的吡咯烷基和哌啶基化合物以及相关的治疗方法 | |
| JP2020519694A (ja) | オレキシン受容体アンタゴニス | |
| KR20180050408A (ko) | 국부 약물 전달용의 비스테로이드성 글루코코르티코이드 수용체 조절제 | |
| HK1214814B (en) | Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases | |
| JPWO2014199960A1 (ja) | グリシントランスポーター阻害物質 | |
| TW201714884A (zh) | 新穎化合物 | |
| AU2015202475A1 (en) | Piperidine derivatives as nk1 antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20161114 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161130 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161130 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170908 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170907 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171208 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171222 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180117 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6279605 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |